Organoid technology has revolutionized the fieldof biomedicine and drug development.

BiomOrgan Limited, a life science company wasfounded in 2021 by a group of top-tier organoidscientists from HKU Medicine led by Prof. ZHOUJie. At BiomOrgan, we are at the forefront of thistransformative technology, leveraging our propri-etary respiratory organoid platform and scientificexpertise to develop cuttingedge organoid cultureproducts and organoid-based services for bothacademia and industry.

Our mission is to harness the immense potentialof organoid technology to address diverse biomedical, translational, and pharmaceutical challengesincluding disease modelling, drug screening, viralsurveillance, and personalized medicine.

Our preclinical capabilities include first-classorganoid culture media, ready-to-use organoids,cryopreserved organoids and developing variousorganoid models including cancer organoids fordrug efficacy and safety testing. Our ultimate goalsare to realize the great potential of organoid tech-nology, to facilitate biomedical research anddevelopment, and to make Hong Kong an interna-tional hub of organoid technology.